BASKING RIDGE, N.J., March 19, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for.

BASKING RIDGE, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore SapphireTM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19. The EUA includes data from early clinical and non-clinical work that examined the use of the company’s VNS, including non-invasive therapy, in several pilot studies that involved patients with a variety of respiratory disorders.

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...

BASKING RIDGE, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) headquartered in St. Louis, has elected to make gammaCoreTM a preferred brand on all of its Standard National Formularies for those benefit designs that do not differentiate between drugs and devices at a monthly co-pay of roughly $25- $45.

BASKING RIDGE, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor. Under the terms of the purchase agreement, electroCore will, at its sole option and discretion, have the right, but not the obligation to sell up to $25 million of its common stock to Lincoln Park over a 36-month period.

BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will continue to be reimbursed for those patients in England who suffer from cluster headache and respond to our therapy.

BASKING RIDGE, N.J., May 07, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for.

BASKING RIDGE, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020. Ms. Cox also served on electroCore’s Audit and Nominating and Governance Committees. Michael Atieh, who joined the company’s Board in June 2018, will assume the role of Chairman.

BASKING RIDGE, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth quarter of 2019, and full-year revenue guidance for 2020. FSS: The company’s decision to redeploy a significant portion of its sales function to FSS is having a positive impact, as 54 Veterans Administration (VA) and Department of Defense (DoD) military treatment facilities purchased gammaCore™ products during the fourth quarter, up from 48 during the third quarter of 2019 and 35 during the second quarter of 2019.

The investors in electroCore, Inc.'s (NASDAQ:ECOR) will be rubbing their hands together with glee today, after the...

BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided an update on ongoing nVNS COVID-19 initiatives. The company announced today that an investigator-initiated, randomized, controlled clinical trial of nVNS therapy has commenced enrolling COVID-19 patients in Spain.

BASKING RIDGE, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has received Section 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the company’s submission seeking to expand the label indication of its gammaCore therapy to include the prevention of migraine in adult patients. “We are grateful to the FDA for clearing the expanded use of our novel gammaCore vagus nerve stimulation device into the prevention of migraine headache in adults who frequently suffer from this incapacitating condition,” stated  Peter Staats M.D., Chief Medical Officer of electroCore.

Top Ranked Momentum Stocks to Buy for March 31st

BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.

BASKING RIDGE, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of three new independent members to its Board of Directors effective April 2, 2020. The newly appointed board members are John Gandolfo, Thomas Patton and Peter Cuneo.

electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Top Ranked Momentum Stocks to Buy for April 3rd

BASKING RIDGE, N.J., April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) technology  available to the broadest possible patient population within our approved adult headache indications,” said Daniel Goldberger, Chief Executive Officer. Expansion of the gammaCore label: On March 26, 2020, the company was informed that it had received Section 510(k) clearance from the FDA of its submission seeking to expand the label indication of its gammaCore therapy to include the prevention of migraine in adult patients.

NEW YORK, NY / ACCESSWIRE / March 23, 2020 / electroCore, Inc. (NASDAQ:ECOR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 23, 2020 at 4:45 PM ...

Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm  ET BASKING RIDGE, N.J., March 23, 2020 -- electroCore,.